Recent advances in mesalamine colonic delivery systems
Future Journal of Pharmaceutical Sciences, 2020 Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing ...
Mohammad F. Bayan, Rana F. Bayan
doaj +1 more source
An Orally Administered Redox Nanoparticle That Accumulates in the Colonic Mucosa and Reduces Colitis in Mice [PDF]
, 2012 Background & AimsDrugs used to treat patients with ulcerative colitis are not always effective because of nonspecific distribution, metabolism in the gastrointestinal tract, and side effects. We designed a nitroxide radical-containing nanoparticle (RNPO)
Matsui Hirofumi +6 more
core +1 more source
Suppository treatment in ulcerative proctitis
European Journal of Inflammation, 2021 Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on
Yingjie Si +3 more
doaj +1 more source
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. [PDF]
, 2015 Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir.
Jakab, Simona +4 more
core +1 more source
Recent advances in understanding and managing diverticulitis. [PDF]
, 2018 In the past few decades, the increasing socioeconomic burden of acute diverticulitis (AD) has become evident, and with the growth of the population age, this significant economic impact will likely continue to rise. Furthermore, recent evidence showed an
Annibale, Bruno +4 more
core +2 more sources
Probiotics in the treatment of diverticular disease. A systematic review [PDF]
, 2016 BACKGROUND AND AIMS: Diverticular disease is a common gastrointestinal condition. Low-grade inflammation and altered intestinal microbiota have been identified as factors contributing to abdominal symptoms.
ANNIBALE, Bruno +5 more
core +1 more source
Frontiers in Immunology, 2022 Mesalamine (MES), also known as 5-aminosalicylic acid, is effective in treating mild to moderate ulcerative colitis (UC). The mechanisms of its actions are not fully elucidated.
Yonggang Huang +4 more
semanticscholar +1 more source
Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it? [PDF]
, 2009 Inflammatory bowel diseases (IBD) are chronic diseases with a relapsing-remitting disease course necessitating lifelong treatment. However, non-adherence has been reported in over 40% of patients, especially those in remission taking maintenance ...
Lakatos, Péter László
core +2 more sources
Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
Journal of clinical biochemistry and nutrition, 2022 Mesalamine is a key drug in the treatment of ulcerative colitis (UC) for both induction and maintenance therapy. On the other hand, it is known that there are some cases of mesalamine intolerance that are difficult to distinguish from symptoms due to ...
Y. Minagawa +19 more
semanticscholar +1 more source
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α [PDF]
The Korean Journal of Internal Medicine, 2022 The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties.
Jihye Park, Jae Hee Cheon
doaj +1 more source